Geode Capital Management LLC recently announced the acquisition of new stake in Neximmune Inc (NASDAQ:NEXI). The institutional investor has increased its shareholding in the Healthcare company by 75.21% to 4326.0 shares with purchase of 1857.0 shares. This fresh investment now brings its stake to 0.41% valued currently at $10728.0.
With over 6.21 million Neximmune Inc (NEXI) shares trading Monday and a closing price of $7.57 on the day, the dollar volume was approximately $47.03 million. The shares have shown a positive half year performance of 7.87% and its price on 01/08/24 gained nearly 22.49%. Currently, there are 1.04M common shares owned by the public and among those 0.66M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Neximmune Inc are Vanguard Extended Market Index Fu, Fidelity Extended Market Index Fu, and Bridgeway Ultra Small Company Mar. Vanguard Extended Market Index Fu owns 3892.0 shares of the company’s stock, all valued at over $9652.0. The company sold 1.0 shares recently to bring their total holdings to about 0.37% of the shares outstanding. Bridgeway Ultra Small Company Mar now owns shares totaling to 0.19% of the shares outstanding.
Shares of Neximmune Inc (NASDAQ: NEXI) opened at $6.34, up $0.16 from a prior closing price of $6.18. However, the script later moved the day high at 9.44, up 22.49%. The company’s stock has a 5-day price change of 240.99% and 63.41% over the past three months. NEXI shares are trading 240.99% year to date (YTD), with the 12-month market performance down to -15.30% lower. It has a 12-month low price of $1.25 and touched a high of $20.35 over the same period. NEXI has an average intraday trading volume of 1.42 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 135.46%, 145.24%, and 22.50% respectively.
Institutional ownership of Neximmune Inc (NASDAQ: NEXI) shares accounts for 16.11% of the company’s 1.04M shares outstanding. Mutual fund holders own 0.96%, while other institutional holders and individual stakeholders account for 15.16% and — respectively.
It has a market capitalization of $8.02M and a beta (3y monthly) value of 1.26. The earnings-per-share (ttm) stands at -$267.72. Price movements for the stock have been influenced by the stock’s volatility, which stands at 42.13% over the week and 20.05% over the month.
Analysts forecast that Neximmune Inc (NEXI) will achieve an EPS of $NextDecade Corporation for the current quarter, $4.59 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $NEXI while analysts give the company a high EPS estimate of $Nexa Resources S.A.. Comparatively, EPS for the current quarter was $NEXITY a year ago.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 1 brokerage firm advisors rate Neximmune Inc (NEXI) as a “Strong Buy” at a consensus score of 1.00. Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 0 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the NEXI, a number of firms have released research notes about the stock. Raymond James stated their Outperform rating for the stock in a research note on April 01, 2021, with the firm’s price target at $30.
